Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Deferred Taxes (2019)

Allogene Therapeutics (ALLO) has disclosed Deferred Taxes for 1 consecutive years, with $33000.0 as the latest value for Q3 2019.

  • Quarterly Deferred Taxes changed N/A to $33000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $33000.0 through Sep 2020, changed N/A year-over-year, with the annual reading at -$119000.0 for FY2018, N/A changed from the prior year.
  • Deferred Taxes hit $33000.0 in Q3 2019 for Allogene Therapeutics, up from -$159000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $33000.0 in Q3 2019 to a low of -$159000.0 in Q2 2019.